Literature DB >> 10981126

Hypertension and single nucleotide polymorphisms.

M J Rieder1, D A Nickerson.   

Abstract

Hypertension is a common, complex disease phenotype that has been intensively studied to identify susceptibility loci in humans. Candidate genes continue to be uncovered via genetic analysis in model organisms through linkage analysis with families and/or sib-pairs and through association studies using sequence variants in genes that play a role in key pathways regulating blood pressure in humans, such as the renin-angiotensin system (RAS). Recent studies exploring the sequence diversity in human candidate genes suggest that the distribution and organization of single nucleotide polymorphisms (SNPs) within and among human populations is complex. Issues related to the use of SNPs in analyzing the genetic determinants of hypertension are illustrated using recent studies on the angiotensin-converting enzyme (ACE).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10981126     DOI: 10.1007/s11906-000-0057-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  50 in total

Review 1.  Molecular aspects of blood pressure regulation.

Authors:  D E Crews; S R Williams
Journal:  Hum Biol       Date:  1999-08       Impact factor: 0.553

2.  Fine-mapping of an ancestral recombination breakpoint in DCP1.

Authors:  M Farrall; B Keavney; C McKenzie; M Delépine; F Matsuda; G M Lathrop
Journal:  Nat Genet       Date:  1999-11       Impact factor: 38.330

3.  A homogeneous, ligase-mediated DNA diagnostic test.

Authors:  X Chen; K J Livak; P Y Kwok
Journal:  Genome Res       Date:  1998-05       Impact factor: 9.043

4.  Association of genetic variation with interindividual variation in ambulatory blood pressure.

Authors:  G L Schwartz; S T Turner; C F Sing
Journal:  J Hypertens       Date:  1996-02       Impact factor: 4.844

5.  Generation and analysis of 280,000 human expressed sequence tags.

Authors:  L D Hillier; G Lennon; M Becker; M F Bonaldo; B Chiapelli; S Chissoe; N Dietrich; T DuBuque; A Favello; W Gish; M Hawkins; M Hultman; T Kucaba; M Lacy; M Le; N Le; E Mardis; B Moore; M Morris; J Parsons; C Prange; L Rifkin; T Rohlfing; K Schellenberg; M Bento Soares; F Tan; J Thierry-Meg; E Trevaskis; K Underwood; P Wohldman; R Waterston; R Wilson; M Marra
Journal:  Genome Res       Date:  1996-09       Impact factor: 9.043

6.  Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia.

Authors:  J P O'Malley; C L Maslen; D R Illingworth
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

7.  Analysis of the apo E/apo C-I, angiotensin converting enzyme and methylenetetrahydrofolate reductase genes as candidates affecting human longevity.

Authors:  D Galinsky; C Tysoe; C E Brayne; D F Easton; F A Huppert; T R Dening; E S Paykel; D C Rubinsztein
Journal:  Atherosclerosis       Date:  1997-03-21       Impact factor: 5.162

8.  Sequence variation in the human angiotensin converting enzyme.

Authors:  M J Rieder; S L Taylor; A G Clark; D A Nickerson
Journal:  Nat Genet       Date:  1999-05       Impact factor: 38.330

9.  DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene.

Authors:  D A Nickerson; S L Taylor; K M Weiss; A G Clark; R G Hutchinson; J Stengård; V Salomaa; E Vartiainen; E Boerwinkle; C F Sing
Journal:  Nat Genet       Date:  1998-07       Impact factor: 38.330

10.  Human SA gene locus as a candidate locus for essential hypertension.

Authors:  N Iwai; N Ohmichi; K Hanai; Y Nakamura; M Kinoshita
Journal:  Hypertension       Date:  1994-03       Impact factor: 10.190

View more
  1 in total

1.  The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: A genetic association study in Brazilian patients.

Authors:  Denise S Pinheiro; Rodrigo S Santos; Paulo C B Veiga Jardim; Elisangela G Silva; Angela A S Reis; Gustavo R Pedrino; Cirano J Ulhoa
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.